How does copper peptide work? GHK-Cu and MMP-2

MMP-2 and its inhibitors

Fibroblasts maintain much of the supporting material around cells. That material, the extracellular matrix, includes collagen. Maintaining it involves removal as well as production. The MMP-2 experiment captures both sides of that work, and that double action is its appeal.

MMP-2 is a matrix metalloproteinase, an enzyme involved in breaking down matrix proteins. In fibroblast cultures, GHK-Cu increased its expression and its messenger RNA, the intermediate instruction used in making a protein. TIMP-1 and TIMP-2 increased alongside it. These inhibitors constrain metalloproteinases.

I hesitate over ‘building skin’ as a description of this experiment. It describes a change in the balance of tissue turnover. The experiment measured cultured cells, so the next question is how that balance behaves in living tissue, with its existing damage, inflammation and supply of copper. The culture result gives the question substance; a clinical outcome still needs to be measured.

Free GHK and GHK-Cu

The comparison in Simeon’s study is unusually useful: free GHK failed to reproduce the MMP-2 response seen with the copper complex. For this measured effect, the copper-bound form mattered. ‘Compound’ becomes an experimentally useful word at exactly this fork.

GHK-Cu holds copper through several binding sites on the peptide, a form of binding called chelation. The tissue-remodelling review discusses copper-dependent work involving lysyl oxidase, which helps cross-link collagen and elastin, and antioxidant activity. That helps explain why attaching copper can change the available biology.

There is an instructive complication. In the SPARC-derived peptide experiments, breakdown of the protein SPARC released copper-binding peptides, including GHK and KGHK, that stimulated blood-vessel formation in endothelial-cell cultures in vitro and in an in vivo angiogenesis assay. KGHK was the most potent, and prior copper binding was unnecessary for that activity. The requirement found in the MMP-2 cultures therefore needs its experimental boundary. I like this exception: it stops the MMP-2 result from swallowing the whole peptide family.

Gene expression after GHK

The gene-data review describes GHK altering expression of approximately 31.2% of human genes at a change threshold of 50% or greater. Among affected genes, 59% were upregulated and 41% downregulated. These are gene-activity measurements from cultured-cell datasets and analysis of them, rather than changes demonstrated across a treated person's body.

The protein-clearance system is the category I linger over: 41 genes increased in activity and 1 decreased. It fits the broader interest in turnover, but gene activity alone leaves open which proteins were ultimately made and what the tissue did. The thresholded table contains about 2,100 genes; the often-repeated 4,000 figure draws on broader extrapolations.

Much of this line of work comes from Pickart and colleagues. Reproducing the gene findings at protein level in living tissue would give the rejuvenation hypothesis firmer support. For now, the gene analysis offers several experiments worth doing.

The stability of the complex

The chemical partnership also depends on its surroundings. Formulation research reviewed in 2025 describes poor passage of native GHK through the outer skin barrier and ways of changing delivery. The earlier skin-regeneration review discusses the stability of the copper complex: mildly acidic conditions near pH 5–6.5 are favourable, while strongly acidic mixtures and vitamin C below about pH 3.5 can disrupt it.

Those observations concern formulation chemistry. They do not settle the performance of every finished cream or provide a routine for combining products. Evidence of intact GHK-Cu at the measured tissue would answer a useful chemical question about the finished preparation.